Bronchopulmonary Dysplasia – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Bronchopulmonary Dysplasia – Pipeline Review, H2 2019’, provides an overview of the Bronchopulmonary Dysplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia

– The report reviews pipeline therapeutics for Bronchopulmonary Dysplasia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Bronchopulmonary Dysplasia therapeutics and enlists all their major and minor projects

– The report assesses Bronchopulmonary Dysplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advent Therapeutics Inc

Airway Therapeutics LLC

Ayuvis Research Inc

Chiesi Farmaceutici SpA

Ethypharm SA

Insmed Inc

MediPost Co Ltd

Meridigen Biotech Co Ltd

Orphanix GmbH

Radikal Therapeutics Inc

Syntrix Biosystems Inc

Takeda Pharmaceutical Co Ltd

The Cell Factory BVBA

Therabron Therapeutics Inc

Trimunocor Ltd

United Therapeutics Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bronchopulmonary Dysplasia - Overview

Bronchopulmonary Dysplasia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bronchopulmonary Dysplasia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development

Advent Therapeutics Inc

Airway Therapeutics LLC

Ayuvis Research Inc

Chiesi Farmaceutici SpA

Ethypharm SA

Insmed Inc

MediPost Co Ltd

Meridigen Biotech Co Ltd

Orphanix GmbH

Radikal Therapeutics Inc

Syntrix Biosystems Inc

Takeda Pharmaceutical Co Ltd

The Cell Factory BVBA

Therabron Therapeutics Inc

Trimunocor Ltd

United Therapeutics Corp

Bronchopulmonary Dysplasia - Drug Profiles

AT-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

caffeine citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFMEV-132 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Bronchopulmonary Dysplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mecasermin rinfabate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit FLT1 for Bronchopulmonary Dysplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

perfluorooctyl bromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pioglitazone + B-YL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pneumostem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-908 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Replace Surfactant Protein D for Bronchopulmonary Dysplasia and Lung Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize TLR-4 for Bronchopulmonary Dysplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SX-576 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMC-11901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UNEX-42 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bronchopulmonary Dysplasia - Dormant Projects

Bronchopulmonary Dysplasia - Discontinued Products

Bronchopulmonary Dysplasia - Product Development Milestones

Featured News & Press Releases

Aug 23, 2019: Medipost’s Pneumostem gets FDA’s fast-track designation

May 15, 2019: Meridigen new Neonatal Stem Cell Drug received TFDA Approval for Clinical Trial

Feb 27, 2019: Esperite N.V. with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of bronchopulmonary dysplasia.

Nov 06, 2018: Esperite Group with The Cell Factory expands its extracellular vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia

Aug 24, 2018: Airway Therapeutics announces appointment of chief medical officer

Jun 02, 2016: Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants

May 25, 2016: Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants

May 03, 2016: MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease

Apr 28, 2016: Therabron Therapeutics Receives FDA Fast Track Designation for rhCC10 for the Prevention of Chronic Lung Disease Related to Premature Birth

Apr 13, 2016: Therabron Therapeutics Receives Notice of Allowance for New Patent Supporting the Recombinant CC10 Technology Platform

Mar 02, 2016: Therabron Therapeutics Announces New Study Aimed at the Creation of Multiple Novel Isoforms of the Company Lead Product Candidate

Dec 08, 2015: Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial

Oct 20, 2015: Therabron Therapeutics Receives Notice of Allowance for New EU Patent Supporting its Recombinant CC10 Technology Platform

Jul 21, 2015: Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program

May 13, 2015: Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Table 1: Number of Products under Development for Bronchopulmonary Dysplasia, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Universities/Institutes, H2 2019

Table 4: Products under Development by Companies, H2 2019

Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 6: Products under Development by Universities/Institutes, H2 2019

Table 7: Number of Products by Stage and Target, H2 2019

Table 8: Number of Products by Stage and Mechanism of Action, H2 2019

Table 9: Number of Products by Stage and Route of Administration, H2 2019

Table 10: Number of Products by Stage and Molecule Type, H2 2019

Table 11: Bronchopulmonary Dysplasia – Pipeline by Advent Therapeutics Inc, H2 2019

Table 12: Bronchopulmonary Dysplasia – Pipeline by Airway Therapeutics LLC, H2 2019

Table 13: Bronchopulmonary Dysplasia – Pipeline by Ayuvis Research Inc, H2 2019

Table 14: Bronchopulmonary Dysplasia – Pipeline by Chiesi Farmaceutici SpA, H2 2019

Table 15: Bronchopulmonary Dysplasia – Pipeline by Ethypharm SA, H2 2019

Table 16: Bronchopulmonary Dysplasia – Pipeline by Insmed Inc, H2 2019

Table 17: Bronchopulmonary Dysplasia – Pipeline by MediPost Co Ltd, H2 2019

Table 18: Bronchopulmonary Dysplasia – Pipeline by Meridigen Biotech Co Ltd, H2 2019

Table 19: Bronchopulmonary Dysplasia – Pipeline by Orphanix GmbH, H2 2019

Table 20: Bronchopulmonary Dysplasia – Pipeline by Radikal Therapeutics Inc, H2 2019

Table 21: Bronchopulmonary Dysplasia – Pipeline by Syntrix Biosystems Inc, H2 2019

Table 22: Bronchopulmonary Dysplasia – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Table 23: Bronchopulmonary Dysplasia – Pipeline by The Cell Factory BVBA, H2 2019

Table 24: Bronchopulmonary Dysplasia – Pipeline by Therabron Therapeutics Inc, H2 2019

Table 25: Bronchopulmonary Dysplasia – Pipeline by Trimunocor Ltd, H2 2019

Table 26: Bronchopulmonary Dysplasia – Pipeline by United Therapeutics Corp, H2 2019

Table 27: Bronchopulmonary Dysplasia – Dormant Projects, H2 2019

Table 28: Bronchopulmonary Dysplasia – Discontinued Products, H2 2019

List of Figures

List of Figures

Figure 1: Number of Products under Development for Bronchopulmonary Dysplasia, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Routes of Administration, H2 2019

Figure 10: Number of Products by Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports